Pharmacogenetics: A tool for individualising antineoplastic therapy

Clinical Pharmacokinetics

Volumn 39, Issue 5, 2000, Pages 315-325

  Innocenti, F ^a   Iyer, L ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMONAFIDE; ANTINEOPLASTIC AGENT; GLUCURONOSYLTRANSFERASE; IRINOTECAN; MERCAPTOPURINE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG DERIVATIVE; FLUOROURACIL; IMIDE; ISOQUINOLINE DERIVATIVE; METHYLTRANSFERASE; NAPHTHALIMIDE DERIVATIVE; OXIDOREDUCTASE; THIOPURINE METHYLTRANSFERASE;

CANCER CHEMOTHERAPY; DOSE CALCULATION; DOSE RESPONSE; DRUG METABOLISM; ENZYME INACTIVATION; GENE INACTIVATION; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; HUMAN; LEUKEMIA; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; GENETICS; METABOLISM;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; IMIDES; ISOQUINOLINES; METHYLTRANSFERASES; NAPHTHALIMIDES; OXIDOREDUCTASES; PHARMACOGENETICS; PHENOTYPE;

EID: 0033626025     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039050-00001     Document Type: Review

References (114)

1. Factors involved in clinical pharmacology variability in oncology
2. Pharmacogenetics and cancer chemotherapy
3. Inherited variations in drug-metabolizing enzymes: Significance in clinical oncology
4. Technologies for detecting genetic polymorphisms in pharmacogenomics
5. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency
6. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine
7. Purine substrates for human thiopurine methyltransferase
8. Thiopurine methyl-transferase: Aromatic thiol substrates and inhibition by benzoic acid derivatives
9. Genetic variation in response to 6-mercaptopurine for childhood acute lympho-blastic leukaemia
10. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia
11. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency
12. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
13. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia
14. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-Mercaptopurine dosage strategies
15. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
16. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
17. 6-Mercaptopurine cumulative dose: A critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia
18. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism
19. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
20. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms
21. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
22. Human thiopurine methyltransferase pharmacogenetics: Kindred with a terminal exon splice junction mutation that results in loss of activity
23. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
24. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
25. Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals
26. Thiopurine methyltransferase alleles in British and Ghanaian populations
27. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population
28. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
29. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
30. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
31. Thiopurine methyltransferase activity in American white subjects and black subjects
32. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
33. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations
34. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
35. Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity
36. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia
37. 6-Mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia
38. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate
39. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
40. Population study of dihydropyrimidine dehydrogenase in cancer patients
41. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
42. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
43. Structural organization of the human dihydropyrimidine dehydrogenase gene
44. Characterization of the human dihydropyrimidine dehydrogenase gene
45. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea
46. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
47. Nomenclature for human DPYD alleles
48. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
49. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
50. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
51. Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G→A point mutation
52. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment With topical 5-fluorouracil
53. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
54. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
55. Cloning and initial characterization of the human DPYD gene promoter
56. Dihydropyrimidine dehydrogenase activity in cancer patients
57. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population
58. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
59. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency
60. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: Major implications for the detection of partly deficient patients
61. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
62. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver
63. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities
64. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
65. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
66. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
67. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
68. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy
69. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
70. Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
71. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome
72. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency
73. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity
74. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity
75. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
76. Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency
77. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy
78. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity
79. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
80. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients
81. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
82. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
83. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
84. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
85. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
86. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
87. Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes
88. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
89. Genetic variation in bilirubin UDP-glucuronyltransferase gene promoter and Gilbert's syndrome
90. UGT*1 genotyping in a Canadian Inuit population
91. Population studies on Gilbert's syndrome
92. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates
93. The UGT1A1*28 allele is relatively rare in a Japanese population
94. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
95. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: Relationships to serum bilirubin concentrations
96. Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase 1 (UGT1A1) gene
97. 8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome
98. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese
99. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucurono-syltransferase gene: A common missense mutation among Japanese, Koreans and Chinese
100. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese
101. Three Japanese patients with Crigler-Najjar syndrome type I carry an identical non-sense mutation in the gene for UDP-glucuronosyltransferase
102. The genetic basis of Gilbert's syndrome
103. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
104. High variability in SN-38 glucuronidation in liver samples from African population as predicted by UGT1A1 genotypes
105. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
106. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case report
107. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11)
108. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage
109. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer-a cancer and leukemia group B study (CALGB 8642)
110. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans
111. Genetic control of isoniazid metabolism in man
112. Paradoxical relationship between acetylator phenotype and amonafide toxicity
113. Phase I study of amonafide dosing based on acetylator phenotype
114. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender